Reprotect Buffergel polyacrylic gel contraceptive's vaginal irritation rate studied by NIAID.
This article was originally published in The Tan Sheet
Executive Summary
BUFFERGEL CONTRACEPTIVE NIAID/HIVNET U.S. PHASE I CLINICAL TRIAL will be completed in September, Buffergel owner Reprotect of Baltimore, Md., said. The company owns the rights to market the polyacrylic acid gel upon which Buffergel is based; the gel was created by company founders Richard Cone, PhD, and Kevin Whaley, PhD, Johns Hopkins University, and Thomas Moench, MD, formerly with Hopkins, now medical director of Reprotect. The National Institute of Allergy & Infectious Diseases, through its HIVNET international HIV research network, is interested in the product as a possible prophylaxis against transmission of human immunodeficiency virus.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning